Facilitating matched pairing and expression of TCR chains introduced into human T cells.

Adoptive transfer of T lymphocytes is a promising treatment for a variety of malignancies but often not feasible due to difficulties generating T cells that are reactive with the targeted antigen from patients. To facilitate rapid generation of cells for therapy, T cells can be programmed with genes encoding the alpha and beta chains of an antigen-specific T-cell receptor (TCR). However, such exogenous alpha and beta chains can potentially assemble as pairs not only with each other but also with endogenous TCR alpha and beta chains, thereby generating alphabetaTCR pairs of unknown specificity as well as reducing the number of exogenous matched alphabetaTCR pairs at the cell surface. We demonstrate that introducing cysteines into the constant region of the alpha and beta chains can promote preferential pairing with each other, increase total surface expression of the introduced TCR chains, and reduce mismatching with endogenous TCR chains. This approach should improve both the efficacy and safety of ongoing efforts to use TCR transfer as a strategy to generate tumor-reactive T cells.

[1]  L. Sherman,et al.  Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. , 1992, Science.

[2]  B. Matthews,et al.  Substantial increase of protein stability by multiple disulphide bonds , 1989, Nature.

[3]  T. Schumacher,et al.  T-cell-receptor gene therapy , 2002, Nature Reviews Immunology.

[4]  C Benoist,et al.  How much TCR does a T cell need? , 2001, Immunity.

[5]  J. Bonifacino,et al.  Pairwise, cooperative and inhibitory interactions describe the assembly and probable structure of the T‐cell antigen receptor. , 1991, The EMBO journal.

[6]  M. Kalos,et al.  Transfer of Specificity for Human Immunodeficiency Virus Type 1 into Primary Human T Lymphocytes by Introduction of T-Cell Receptor Genes , 2000, Journal of Virology.

[7]  H. Reid,et al.  Cyclosporin A abrogates the acquired immunity to cutaneous reinfection with the parapoxvirus orf virus , 1996, Immunology.

[8]  G. Gao,et al.  Production of soluble αβ T‐cell receptor heterodimers suitable for biophysical analysis of ligand binding , 2008, Protein science : a publication of the Protein Society.

[9]  M. Schuler,et al.  Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man , 2002, Gene Therapy.

[10]  I. Plavec,et al.  Enhanced transgene expression in quiescent and activated human CD8+ T cells. , 2004, Human gene therapy.

[11]  W. Schamel,et al.  Differences in pairing and cluster formation of T cell receptor α- and β-chains in T cell clones and fusion hybridomas , 2005 .

[12]  J. Lippincott-Schwartz,et al.  Failure to synthesize the T Cell CD3-ζ chain: Structure and function of a partial T cell receptor complex , 1988, Cell.

[13]  Pedro Romero,et al.  Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression , 2006, Immunologic research.

[14]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[15]  S. Rosenberg,et al.  Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. , 1999, Journal of immunology.

[16]  E. Coligan.  Current protocols in immunology , 1991 .

[17]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[18]  Hans-Georg Rammensee,et al.  The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy , 2004, Cancer Immunology, Immunotherapy.

[19]  M. Nishimura,et al.  Transfer of TCR Genes into Mature T Cells Is Accompanied by the Maintenance of Parental T Cell Avidity , 2003, The Journal of Immunology.

[20]  S. Rosenberg,et al.  High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens , 2003, The Journal of Immunology.

[21]  T. Blankenstein,et al.  Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors , 2004, European journal of immunology.

[22]  Hans J. Stauss,et al.  Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer , 2001, Nature Immunology.

[23]  Pedro Romero,et al.  Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. , 2005, Immunity.

[24]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[25]  Steven A. Rosenberg,et al.  Adoptive-cell-transfer therapy for the treatment of patients with cancer , 2003, Nature Reviews Cancer.

[26]  Matthias Theobald,et al.  Designing TCR for cancer immunotherapy. , 2005, Methods in molecular medicine.

[27]  B. Alarcón,et al.  Multivalent structure of an αβT cell receptor , 1999 .

[28]  Yi Li,et al.  Design of Soluble Recombinant T Cell Receptors for Antigen Targeting and T Cell Inhibition* , 2005, Journal of Biological Chemistry.

[29]  D. Lo,et al.  Preferential expression of TCR V alpha regions in CD4/CD8 subsets: class discrimination or co-receptor recognition? , 1998, Immunology today.

[30]  T. Reynolds,et al.  T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients , 1996, Nature Medicine.

[31]  B. Engels,et al.  Articles on similar topics can be found in the following Blood collections Gene Therapy (517 articles) , 2005 .

[32]  Yangbing Zhao,et al.  Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. , 2006, Cancer research.

[33]  E. Reinherz,et al.  Mechanisms Contributing to T Cell Receptor Signaling and Assembly Revealed by the Solution Structure of an Ectodomain Fragment of the CD3ϵγ Heterodimer , 2001, Cell.

[34]  P. Robbins,et al.  A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.

[35]  J W Gratama,et al.  Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR , 2000, Gene Therapy.

[36]  Meir Glick,et al.  Stable, soluble T-cell receptor molecules for crystallization and therapeutics. , 2003, Protein engineering.

[37]  Ian A Wilson,et al.  The specificity of TCR/pMHC interaction. , 2002, Current opinion in immunology.

[38]  H. Ikeda,et al.  Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. , 2005, Blood.

[39]  R. Hagedoorn,et al.  αβ T-Cell Receptor Engineered γδ T Cells Mediate Effective Antileukemic Reactivity , 2006 .

[40]  A. Cope,et al.  The Transmembrane Adaptor Protein Trim Regulates T Cell Receptor (Tcr) Expression and Tcr-Mediated Signaling via an Association with the Tcr ζ Chain , 2001, The Journal of experimental medicine.

[41]  P. Greenberg,et al.  In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire. , 2006, Journal of immunological methods.

[42]  Z. Li,et al.  Structural mutations in the constant region of the T-cell antigen receptor (TCR)beta chain and their effect on TCR alpha and beta chain interaction. , 1996, Immunology.

[43]  Yi Li,et al.  Directed evolution of human T-cell receptors with picomolar affinities by phage display , 2005, Nature Biotechnology.

[44]  A. Lanzavecchia,et al.  From TCR Engagement to T Cell Activation A Kinetic View of T Cell Behavior , 1999, Cell.

[45]  Partho Ghosh,et al.  Structure of the complex between human T-cell receptor, viral peptide and HLA-A2 , 1996, Nature.

[46]  P. Lansdorp,et al.  CD27 Expression Promotes Long-Term Survival of Functional Effector–Memory CD8+Cytotoxic T Lymphocytes in HIV-infected Patients , 2004, The Journal of experimental medicine.

[47]  A. Plückthun,et al.  Folding, heterodimeric association and specific peptide recognition of a murine alphabeta T-cell receptor expressed in Escherichia coli. , 1999, Journal of molecular biology.

[48]  S. Riddell,et al.  The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. , 1990, Journal of immunological methods.

[49]  C. Scheibenbogen,et al.  Wilms' tumour gene 1 (WT1) in human neoplasia , 2005, Leukemia.